Literature DB >> 28765116

Bap1 and Pbrm1: Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma.

Janet Y Leung1,2, William Y Kim3,2,4.   

Abstract

<b/> Large genome sequencing efforts have identified frequent mutations in the histone-modifying and chromatin-remodeling genes BAP1 and PBRM1 in clear cell renal cell carcinoma (ccRCC). In this issue of Cancer Discovery, Gu and colleagues model these genetic events in mice and report that dual inactivation of Vhl with either Bap1 or Pbrm1 results in faithful genetically engineered murine models of ccRCC. Moreover, their work establishes that Bap1 and Pbrm1 are determinants of tumor grade and mTORC1 activation and provocatively suggests that the cell of origin of ccRCC may lie in PAX8-expressing Bowman capsule cells. Cancer Discov; 7(8); 802-4. ©2017 AACRSee related article by Gu et al., p. 900. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765116      PMCID: PMC7549016          DOI: 10.1158/2159-8290.CD-17-0610

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  10 in total

1.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

2.  Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Authors:  Yi-Feng Gu; Shannon Cohn; Alana Christie; Tiffani McKenzie; Nicholas Wolff; Quyen N Do; Ananth J Madhuranthakam; Ivan Pedrosa; Tao Wang; Anwesha Dey; Meinrad Busslinger; Xian-Jin Xie; Robert E Hammer; Renée M McKay; Payal Kapur; James Brugarolas
Journal:  Cancer Discov       Date:  2017-05-04       Impact factor: 39.397

Review 3.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

4.  The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Authors:  Amrita M Nargund; Can G Pham; Yiyu Dong; Patricia I Wang; Hatice U Osmangeyoglu; Yuchen Xie; Omer Aras; Song Han; Toshinao Oyama; Shugaku Takeda; Chelsea E Ray; Zhenghong Dong; Mathieu Berge; A Ari Hakimi; Sebastien Monette; Carl L Lekaye; Jason A Koutcher; Christina S Leslie; Chad J Creighton; Nils Weinhold; William Lee; Satish K Tickoo; Zhong Wang; Emily H Cheng; James J Hsieh
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

5.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

6.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

7.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Authors:  Ignacio Varela; Patrick Tarpey; Keiran Raine; Dachuan Huang; Choon Kiat Ong; Philip Stephens; Helen Davies; David Jones; Meng-Lay Lin; Jon Teague; Graham Bignell; Adam Butler; Juok Cho; Gillian L Dalgliesh; Danushka Galappaththige; Chris Greenman; Claire Hardy; Mingming Jia; Calli Latimer; King Wai Lau; John Marshall; Stuart McLaren; Andrew Menzies; Laura Mudie; Lucy Stebbings; David A Largaespada; L F A Wessels; Stephane Richard; Richard J Kahnoski; John Anema; David A Tuveson; Pedro A Perez-Mancera; Ville Mustonen; Andrej Fischer; David J Adams; Alistair Rust; Waraporn Chan-on; Chutima Subimerb; Karl Dykema; Kyle Furge; Peter J Campbell; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2011-01-19       Impact factor: 49.962

8.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

9.  Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.

Authors:  Sabine Harlander; Désirée Schönenberger; Nora C Toussaint; Michael Prummer; Antonella Catalano; Laura Brandt; Holger Moch; Peter J Wild; Ian J Frew
Journal:  Nat Med       Date:  2017-05-29       Impact factor: 53.440

10.  MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.

Authors:  Sean T Bailey; Aleisha M Smith; Jordan Kardos; Sara E Wobker; Harper L Wilson; Bhavani Krishnan; Ryoichi Saito; Hyo Jin Lee; Jing Zhang; Samuel C Eaton; Lindsay A Williams; Ujjawal Manocha; Dorien J Peters; Xinchao Pan; Thomas J Carroll; Dean W Felsher; Vonn Walter; Qing Zhang; Joel S Parker; Jen Jen Yeh; Richard A Moffitt; Janet Y Leung; William Y Kim
Journal:  Nat Commun       Date:  2017-06-08       Impact factor: 14.919

  10 in total
  3 in total

1.  Identification of prognostic chromatin-remodeling genes in clear cell renal cell carcinoma.

Authors:  Yujing Yang; Chengyuan Wang; Ningde Wei; Ting Hong; Zuyu Sun; Jiawen Xiao; Jiaxi Yao; Zhi Li; Tao Liu
Journal:  Aging (Albany NY)       Date:  2020-11-20       Impact factor: 5.682

2.  Effects of HMGA2 on the epithelial-mesenchymal transition-related genes in ACHN renal cell carcinoma cells-derived xenografts in nude mice.

Authors:  Ying Liu; Guangyao Lv; Jianxin Bai; Lingling Song; Elizabeth Ding; Lin Liu; Yuqin Tian; Qian Chen; Kai Li; Xianfeng Liu; Yan Ding
Journal:  BMC Cancer       Date:  2022-04-19       Impact factor: 4.638

3.  PBRM1 deficiency oncogenic addiction is associated with activated AKT-mTOR signalling and aerobic glycolysis in clear cell renal cell carcinoma cells.

Authors:  Yu Tang; Yan-Hong Jin; Hu-Li Li; Hui Xin; Jin-Dong Chen; Xue-Ying Li; You-Fu Pan
Journal:  J Cell Mol Med       Date:  2022-06-07       Impact factor: 5.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.